Is NCT04959175 recruiting in Philadelphia, PA?

Yes, NCT04959175 is currently recruiting participants at its Philadelphia, PA location. This blood cancer clinical trial is actively enrolling qualified participants.

How do I join the blood cancer clinical trial in Philadelphia?

To join this clinical trial in Philadelphia, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Philadelphia clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Blood Cancer Clinical Trial in Philadelphia, PA

About This Blood Cancer Study in Philadelphia

Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD). The chemotherapy drug cyclophosphamide helps reduce the risk and severity of GVHD. Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side effects while maintaining its effectiveness. Such an approach is being used in an ongoing clinical study at the NIH with promising result

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

- Recipient

Subjects must have a histologically or cytologically confirmed hematologic malignancy with standard indication for allogeneic hematopoietic cell transplantation including, but not limited to, one of the following:

Acute myeloid leukemia in morphologic complete remission (\<5% blasts in the bone marrow, no detectable abnormal peripheral blasts, and no extramedullary disease)

B-cell acute lymphoblastic leukemia in first or subsequent complete remission

T-cell acute lymphoblastic leukemia in first or subsequent complete remission

Myelodysplastic syndrome of intermediate or higher score by the Revised International Prognostic Scoring System (IPSS-R)

Primary myelofibrosis of intermediate-2 or higher risk by the DIPSS

Chronic myelomonocytic leukemia

Chronic myelogenous leukemia resistant to or intolerant of \>=3 tyrosine kinase inhibitors or with history of accelerated phase or blast crisis

B-cell lymphoma including Hodgkin lymphoma that has relapsed within 1 year of completion of primary treatment, after autologous transplantation or has progressed through at least 2 lines of therapy

Chronic lymphocytic leukemia with 17p deletion and/or unmutated IgHV or refractory or intolerant of both BTK and PI3K inhibitors

Mature T or NK neoplasms as defined in the WHO guidelines of sufficient type and severity for allogeneic HCT based on the Prognostic Index for T-cell lymphoma (PIT) score of low-intermediate risk or higher60 or on recently published clinical practice guidelines

Hematologic malignancy of dendritic cell or histiocytic cell type

Multiple myeloma, stage III, relapsing after therapy with both a proteasome inhibitor and an immunomodulatory drug (IMiD)

Age 60-85 years, or age 18-60 years and unfit for myeloablative conditioning. Reasons for unfitness for myeloablative conditioning include:

Prior myeloablative HCT

Prior exposure to inotuzumab, gemtuzumab, or other agent that increases the risk for sinusoidal obstruction syndrome.

Significant organ dysfunction (e.g., creatinine or liver enzymes above the upper limit of normal or EGFR \<=70 ml/min/1.73sq.m; prior sinusoidal obstruction syndrome, hepatic fibrosis, hepatic steatosis, or nodular regenerative hyperplasia; reduced ejection fraction \<55% or focal hypokinesis, FEV1 or adjusted DLCO \<75% of predicted)

Hematopoietic Cell Transplantation- Comorbidity Index (HCT-CI) \>= 3

Subject refusal of MAC (including subjects insistent on trying to maintain fertility)

Pre-frail or frail by Fried s frailty phenotype

Karnofsky performance score \<80

Significant life-threatening toxicities associated with prior chemotherapy

Co-morbidity considered by the treating physician to be

Exclusion Criteria

At least one potentially suitable HLA-matched related, HLA-haploidentical first degree or collateral related, HLA-matched unrelated, or \>=5/10 HLA-mismatched unrelated donor.

Karnofsky performance score \>=60

Ability of subject to understand and the willingness to sign a written informed consent document.

Adequate organ function defined as possessing all of the following:

Cardiac ejection fraction \>=35%;

Forced expiratory volume-1, forced vital capacity, and diffusing capacity of the lung for carbon monoxide (corrected for hemoglobin) all of \>=40% predicted;

Serum creatinine clearance of \>=45 ml/minute calculated using the Cockcroft-Gault equation;

Total bilirubin \<=2X the upper limit of normal;

Alanine aminotransferase and aspartate aminotransferase \<=5X the upper limit of normal.

Nonmyeloablative conditioning is toxic to the developing human fetus and is teratogenic. For this reason, the following measures apply:

Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one year post-transplant.

Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

WOCBP must have a negative serum or urine pregnancy test within 7 days prior to enrollment.

For NIH treated subjects only: subjects requiring standard therapies to prepare for HCT should be referred in remission, if possible. However, these diseases are often aggressive and require swift evaluation for HCT while concurrently attempting to establish disease control through the administration of standard therapies. If ongoing therapy for the underlying disease outside of the NIH is not in the best interest of the subject according to the clinical judgment of the NIH PI, then the subject may receive standard treatment for his/her underlying hematologic malignancy as a bridge to HCT on this protocol, prior to starting the research phase of the study. If it becomes apparent that the subject will not be able to proceed to HCT, then he/she must come off study. Subjects receiving standard therapy will be told about the therapy, associated risks, potential benefits, alternatives to the proposed therapy, and the availability of receiving the same treatment elsewhere, outside of a research protocol. EXCLUSION CRITERIA - Recipient:

Subjects who are receiving any other investigational agents. Prior experimental therapies must have been completed at least 2 weeks prior to the date of beginning conditioning.

Poorly controlled malignant indication for transplantation such as:

Leukemia not having achieved morphologic remission (i.e. bone marrow blasts \>5% or active extramedullary disease)

Lymphoma not having achieved at least a partial response to prior chemotherapy or radiation

Uncontrolled intercurrent illness that in the opinion of the site PI would make it unsafe to proceed with transplantation.

The potential for some of the study medications to be transmissible via breast milk of nursing mothers is unknown. Because there is unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued.

Active malignancy of non-hematopoietic type which is: metastatic, relapsed/refractory to treatment, or locally advanced and not amenable to curative treatment, or limited disease treated with curative intent treatment within the last 2 years. This excludes nonmelanoma skin cancers. INCLUSION CRITERIA - Donor: Related (age \>=12) and unrelated (age \>=18) donors deemed eligible (i.e., evaluated at NIH in accordance with existing institutional Standard Policies and Procedures or evaluated per the standards required by the IRB of the National Marrow Donor Program or applicable registry), and willing to donate research samples will be included. EXCLUSION CRITERIA - Donor: None

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT04959175) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Blood Cancer Treatment Options in Philadelphia, PA

If you're searching for blood cancer treatment options in Philadelphia, PA, this clinical trial (NCT04959175) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced blood cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all blood cancer clinical trials near you to find additional studies recruiting in your area.

Blood Cancer Clinical Trial in Philadelphia, PA

Expert Care in Philadelphia

IRB Approved

No-Cost Care

Apply for This Philadelphia Location

Why Participate?

Simple Process